Camizestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Camizestrant · Etcamah
Marketed by AstraZeneca
NCT04964934 · Phase 3 · active, not recruiting
This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT04644068 (registry estimate)
Reported efficacy
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)
Result source: NCT04964934
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Camizestrant | Vepdegestrant |
|---|---|---|
| PFS, median | —Trial running · NCT07717450 | 3.7 vs 3.6vs FulvestrantNCT056546231 other result
|
| OS, median | —Trial running · NCT07717450 | —Trial running · NCT05909397 |
| ORR | —Trial running · NCT07717450 | 10.9% vs 3.6%vs FulvestrantNCT05654623 |
| Clinical benefit rate | —Trial running · NCT07717450 | 34.3% vs 28.7%vs FulvestrantNCT05654623 |
PFS, median
- Camizestrant
- —Trial running · NCT07717450
- Vepdegestrant
- 3.7 vs 3.6vs FulvestrantNCT05654623
1 other result
- 5 vs 2.1 NCT05654623
OS, median
- Camizestrant
- —Trial running · NCT07717450
- Vepdegestrant
- —Trial running · NCT05909397
ORR
- Camizestrant
- —Trial running · NCT07717450
- Vepdegestrant
- 10.9% vs 3.6%vs FulvestrantNCT05654623
Clinical benefit rate
- Camizestrant
- —Trial running · NCT07717450
- Vepdegestrant
- 34.3% vs 28.7%vs FulvestrantNCT05654623
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Camizestrant: 4 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camizestrant | Vepdegestrant |
|---|---|---|
| Dropout rate | 3.3%75 mga NCT04588298 · Phase 2 show 4 more results3.3%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | 7.8%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | —a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 0%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 | 4%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 4 more results | a hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Vepdegestrant
show 1 more result
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Camizestrant · Etcamah
Marketed by AstraZeneca
NCT04964934 · Phase 3 · active, not recruiting
This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2027 · NCT05774951 (registry estimate)
Reported efficacy
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)
Result source: NCT04964934
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Camizestrant: 4 of 4 rows · Vepdegestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camizestrant | Vepdegestrant |
|---|---|---|
| Dropout rate | 3.3%75 mga NCT04588298 · Phase 2 show 4 more results3.3%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | 7.8%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 7.7%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 6.9%150 mg NCT04588298 · Phase 2 | —a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%75 mga NCT04588298 · Phase 2 show 4 more results0%75 mg NCT04588298 · Phase 2 0%300 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 0%150 mg NCT04588298 · Phase 2 | 4%a NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 4 more results | a hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Vepdegestrant
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Vepdegestrant's landscape